How Oprah Winfrey Became the De Facto Ambassador for the Weight-Loss Drug Revolution

Only Oprah Winfrey seems to be able to create a certain kind of cultural moment. When she appeared in a PEOPLE cover story in December 2023, she openly acknowledged that she had been taking a weight-loss drug. Not in secret. Not as an admission. as a comfort. Within 48 hours, middle-aged women in America were discussing the same topic on every cable news program, wellness podcast, and group chat. It’s difficult to ignore how uncommon that kind of unifying spark has become.

Oprah’s use of a GLP-1 wasn’t the only thing that made the moment land. Many famous people had been, in silence, for a minimum of a year. The framing was the problem. She didn’t express regret. She didn’t present it as a journey toward wellness. She referred to it as “redemption.” Her statement that she was “absolutely done with the shaming” carried the weight of fifty years of public scrutiny, including the magazine covers, the Mr. Blackwell list (“Dumpy, Frumpy and Downright Lumpy”), and the fat wagons she famously rolled onto her own stage in 1988. A press release was not what it was. It was an accounting settlement.

Pharmaceutical companies paid billions for what came next, but they hardly ever received it. Novo Nordisk and Eli Lilly didn’t have to do anything to convince tens of millions of viewers that obesity is a disease, that willpower is a myth, and that the medication “quiets the food noise.” It was a reliable voice with no apparent financial connection to the drug itself. When she hosted “Shame, Blame and the Weight Loss Revolution” on ABC in March 2024, the framing had become ingrained in the public consciousness. The program made the case that obesity is not a moral shortcoming. The medications are not a quick fix. The discussion shifted.

One could be cynical about this. After all, Oprah held a 10% share in WeightWatchers, a company founded sixty years ago on the idea that discipline and points were the solution. Because the legacy model was failing, WeightWatchers had every reason to switch to GLP-1s, and Oprah had every reason to spearhead that change. The timing of her disclosure and WW’s strategic shift toward telehealth and prescription weight-loss services was not, let’s say, coincidental. She has since resigned from the board and donated her shares. Everyone involved seemed to benefit from the plot.

The more fascinating parts of the special, however, had nothing to do with pharmaceuticals. Maggie Ervie, a fifteen-year-old who had been taking Victoza since she was thirteen, had her mother pleading with viewers to “walk a mile in our shoes.” Amy Kane reported that she now looked forward to visiting the doctor for the first time in her life. W. Scott Butsch of the Cleveland Clinic once likened an obese brain to someone submerged and eventually forced to come to the surface. These were not talking points from the pharmaceutical industry. These were the kind of testimonies that Oprah has always been adept at locating—the particular human narrative that lends the abstract argument a sense of inevitability.

The appearance of this long tail is still unknown. The number of GLP-1 prescriptions has increased. There are actual, occasionally serious side effects. Insurance coverage is still a complete mess. Additionally, there is ongoing debate over the cultural shift that Oprah spearheaded—that obesity is a result of biology rather than character—particularly among those who made a living promoting the willpower model. The 72-year-old Oprah claims that she stops eating at four, hikes the mountain behind her Hawaiian home, and uses the drug as a maintenance tool. Like everything she does, the endorsement is wrapped in self-mythology and discipline. Nobody can quite tell yet whether that will be sufficient to keep the new story cohesive or whether the next wave of side-effect stories will tear it apart.